Robot that can draw blood in humans
In this clinical trial involving patients from four countries, half of the participants were randomly allocated to receive vancomycin therapy and the other half received a combination of vancomycin and a penicillin-class antibiotic.
Published today in the journal JAMA , results showed that although the MRSA was killed more quickly, this did not translate to fewer deaths. Surprisingly, combination treatment led to more episodes of kidney injury.
One of the lead researchers, Royal Melbourne Hospital Clinician Researcher at the Doherty Institute, Associate Professor Steven Tong, said this was a significant finding in the future treatment of MRSA infections.
"Clinicians now have the latest evidence as to what works and what doesn't when treating MRSA bloodstream infections, and this trial shows more is not better," Associate Professor Tong said.
This work will now continue with a National Health and Medical Research Council (NHMRC) $5 million grant to conduct the Staphylococcus aureus Network Adaptive Platform trial (SNAP).
"Golden staph is a bacterium that causes over 5000 bloodstream infections a year in Australia, with a mortality rate of 20 per cent, and yet despite these numbers, there is little evidence to guide best management," Associative Professor Tong said.
"This grant brings together a global collaboration to conduct the largest ever clinical trial for Staphylococcus aureus bloodstream infections and address common questions around how to best treat these infections for patients all over the world." Source:
University of Melbourne Journal reference:
Tong, S.Y.C., et al. (2020) Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. A Randomized Clinical Trial. JAMA . doi.org/10.1001/jama.2020.0103 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology